A detailed history of Catalyst Funds Management Pty LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 9,200 shares of EXEL stock, worth $323,748. This represents 0.05% of its overall portfolio holdings.

Number of Shares
9,200
Holding current value
$323,748
% of portfolio
0.05%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $202,032 - $253,920
9,200 New
9,200 $239 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Catalyst Funds Management Pty LTD Portfolio

Follow Catalyst Funds Management Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Funds Management Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Funds Management Pty LTD with notifications on news.